Captor Capital Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Captor Capital has been growing earnings at an average annual rate of 43.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 29.8% per year. Captor Capital's return on equity is 38.3%, and it has net margins of 33%.

Anahtar bilgiler

43.8%

Kazanç büyüme oranı

50.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi7.3%
Gelir büyüme oranı29.8%
Özkaynak getirisi38.3%
Net Marj33.0%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Captor Capital nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

DB:NMV Gelir, gider ve kazançlar (CAD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 245919130
31 Mar 2437-11160
31 Dec 2336-15220
30 Sep 2338-15220
30 Jun 2340-12230
31 Mar 2342-13240
31 Dec 2242-8200
30 Sep 2239-10190
30 Jun 2237-14200
31 Mar 2233-14180
31 Dec 2128-10160
30 Sep 2124-8150
30 Jun 2119-10120
31 Mar 2116-6110
31 Dec 2015-5100
30 Sep 2013-15100
30 Jun 2013-25110
31 Mar 2012-33110
31 Dec 1915-65100
30 Sep 1913-5880
30 Jun 199-48110
31 Mar 196-46140
31 Dec 184-3120
30 Sep 1840120
30 Jun 184350
31 Mar 180410
31 Dec 171410
30 Sep 171410
30 Jun 172510
31 Mar 175810
31 Dec 160-110
30 Sep 160-110
30 Jun 160-220
31 Mar 16-1-210
31 Dec 15-2-420
30 Sep 15-1-420
30 Jun 15-2-420
31 Mar 15-1-320
31 Dec 140-310
30 Sep 140-320
30 Jun 140-220
31 Mar 14-1-330
31 Dec 13-12-1130

Kaliteli Kazançlar: NMV has a high level of non-cash earnings.

Büyüyen Kar Marjı: NMV became profitable in the past.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: NMV has become profitable over the past 5 years, growing earnings by 43.8% per year.

Büyüme Hızlandırma: NMV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Kazançlar vs. Sektör: NMV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).


Özkaynak Getirisi

Yüksek ROE: NMV's Return on Equity (38.3%) is considered high.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin